SEC Tracker
Get the app

Oruka Therapeutics ORKA

Dambkowski Carl (Director) plans to sell 105,000 ORKA shares, about $6.4M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: May 21, 2026
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of Stock Options; Partnership Distribution
  4. 10b5-1 plan adopted: Feb 19, 2026

All of Dambkowski Carl's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Oruka Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. CytomX Therapeutics CTMX public float $372M, Jun 30, 2025
  2. Cronos Group CRON public float $380M, Jun 30, 2025
  3. REGENXBIO RGNX public float $385M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Cryoport CYRX public float $400M, Jun 30, 2025